EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL
Arthur Kaser 1
Bruce E. Sands 2
Marijana Protic 3
Laurent Peyrin-Biroulet 4
Zhantao Lin 4
Rebecca Hozak 4
Vipul Jairath 5
Hilde Carlier 5
Emily Hon 5
Monika Fischer 6
1 University of Cambridge Gastroenterology and Hepatology, Cambridge, United Kingdom
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Eli Lilly and Company, Indianapolis, United States
4 University Hospital of Nancy, University of Lorraine, Vandoeuvre-les-Nancy, France
5 Western University & London Health Sciences Centre, London, Canada
6 Indiana University, Indianapolis, United States
Topic
IBD
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]